DaVita (DVA) Beats Q1 Earnings Estimates, Reiterates View
Zacks Investment Research | May 07, 2018 10:09PM ET
DaVita Inc. (NYSE:DVA) reported first-quarter 2018 adjusted operating earnings of $1.05 per share, beating the Zacks Consensus Estimate of 92 cents. Earnings increased 32.9% on a year-over-year basis.
Total revenues increased 8.3% year over year to $2.85 billion but missed the Zacks Consensus Estimate of $2.96 billion.
DaVita carries a Zacks Rank #3 (Hold).
Business Details
Net dialysis and related lab patient service revenues in the first quarter were $2.62 billion, up 13% year over year. Other revenues were $232 million, down 26.2% on a year-over-year basis.
DaVita saw impressive results from the Kidney Care business. Net consolidated revenues in the segment were $2.85 billion, up 8.3% year over year. Adjusted Kidney Care operating income was $411 million, up 8.2% year over year. As an operating division of DaVita, DaVita Kidney Care focuses on setting worldwide standards for clinical, social and operational practices in kidney care.
Adjusted U.S. dialysis and related lab services operating income in the first quarter was up 4.4% to $433.4 million. U.S. dialysis treatments for the first quarter of 2018 were 7,174,026, or 92,568 treatments per day. This represents an increase of 4.8% year over year.
DaVita Inc. Price, Consensus and EPS Surprise
The company’s patient care costs were up approximately 25 cents per treatment compared with the last reported quarter.
For investors’ notice, the company’s major segment — DaVita Medical Group (“DMG”) — is on track for divestment to Optum, a subsidiary of UnitedHealth Group Inc (NYSE:UNH). This transaction is subject to regulatory approvals and other customary closing conditions. The results of DMG business’ operations have been reported as discontinued in the quarter under review.
Share Repurchase Update
During the first quarter, DaVita repurchased a total of 4.2 million shares for approximately $298 million at an average price of $71.09 per share.
Through May 2, 2018, DaVita has repurchased 8.5 million shares for $574 million on a year-to-date basis. This represents nearly 5% of the company’s total shares outstanding. This also includes approximately $500 million of stock repurchase.
Guidance
DaVita reiterated guidance for 2018.
For 2018, the company projects Kidney Care consolidated operating income in the range of $1.5-$1.6 billion. Operating cash flow from continuing operations is estimated in the range of $1.4-$1.6 billion. Effective tax rate is expected in the range of 26.5-27.5%.
In Conclusion
DaVita ended the first quarter of 2018 on a mixed note with adjusted earnings beating the Zacks Consensus Estimate and revenues missing the same. The company saw impressive results from the Kidney Care business lately. As an operating division of DaVita, DaVita Kidney Care focuses clinical, social and operational practices worldwide. The company’s efforts to control expenses hold promise. A compelling inorganic growth story is another positive.
Get The News You Want
On the flip side, sluggishness in the Other business is a major headwind for DaVita. The company is facing the adverse effects of the pricing pressure in the U.S. medical industry and rise in Medicare insurance costs. The company’s major segment — DaVita Medical Group— has been on track for the divestment to Optum, a subsidiary of UnitedHealth Group Inc. Further, high debt levels, adverse effects of healthcare reforms and increase in Medicare-Advantage beneficiaries are concerns.
Q1 Earnings of MedTech Majors at a Glance
A few better-ranked stocks in the broader medical space, which reported solid earnings this season, are Baxter International Inc. (NYSE:BAX) , Varian Medical Systems, Inc. (NYSE:VAR) and Intuitive Surgical, Inc. (NASDAQ:ISRG) .
While Intuitive Surgical and Varian sport a Zacks Rank #1 (Strong Buy), Baxter carries a Zacks Rank #2 (Buy). You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.